Anticipating changes in the HER2 status of breast tumours with disease progression-towards better treatment decisions in the new era of HER2-low breast cancers.
Fiche publication
Date publication
avril 2023
Journal
British journal of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent, Dr BERTAUT Aurélie, Dr LADOIRE Sylvain, Dr DESMOULINS Isabelle, Dr CHARON-BARRA Céline
Tous les auteurs :
Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, Desmoulins I, Ladoire S, Arnould L
Lien Pubmed
Résumé
HER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We aimed to estimate them between primary and recurrent tumours, and identify predictive factors.
Référence
Br J Cancer. 2023 04 29;: